title: [Expression and diagnosis value of Fascin in non-small cell lung cancer patients].
abstract: OBJECTIVE
  To evaluate the diagnostic significance of Fascin protein in non-small cell lung cancer (NSCLC) patients.
  
  
  METHODS
  Among 110 cases of NSCLC patients and 50 cases of healthy controls, double antibody sandwich enzyme-linked immunosorbent assay (ELISA) was employed to measure the serum levels of Fascin protein, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), scales like squamous cell carcinoma (SCC) antigen, cytokeratin protein 21-1 (CYFRA21-1) and gastrin-releasing peptide (GRP) precursor. Fascin-positive rate (24.4%) in NSCLC patients was significantly higher than that in healthy controls (4%) (P < 0.05).In different clinical stages of non-small cell lung cancer patients, Fascin-positive rate was statistically significant (P < 0.05). The positive rates of Fascin for CEA, CYFRA21-1, NSE, SCC and Pro-GRP were 25.64%, 5.1%, 5.1%, 5.0% and 1.7% respectively.
  
  
  CONCLUSIONS
  As a new tumor marker, Fascin may be used for clinical screening and prognosis in lung cancer.
authors.affiliation: Department of Thoracic, Affiliated Hospital of Neimenggu Medical University, Hohhot 010059, China.
authors.forename: Yu-gang
authors.initials: YG
authors.lastname: Liu
authors.forename: Xu-dong
authors.initials: XD
authors.lastname: Gao
authors.forename: Wen-tao
authors.initials: WT
authors.lastname: Yue
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000175:diagnosis*; D002352:Carrier Proteins / Q000097:blood*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000175:diagnosis*; D008297:Male; D008840:Microfilament Proteins / Q000097:blood*; D008875:Middle Aged
chemical_list: D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D008840:Microfilament Proteins; C020324:fascin